Press release
Intravenous Immunoglobulin Market Deep Research Report with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031"
The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1874
Immunoglobulins are made from a large human plasma pool obtained from at least 100 donors. The intramuscular route of administration is a traditional procedure that is no longer favoured due to its unpleasantness. In recent years, intravenous immunoglobulin has been a lifeline for people with impaired immune systems. The increasing incidences of target disorders, such as primary immunodeficiency disorders, are expected to expand the market. The rising frequency of immunodeficiency illnesses, technological breakthroughs and investments, rising acceptance of immunoglobulin therapy, and an ageing population will likely fuel market revenue growth over the forecast period. IVIG is a sterile, concentrated set of antibodies from healthy persons injected directly into a vein. It is used to treat immune system disorders or to increase immunological response. The expense of diagnosing and treating demyelinating illness is exceptionally high. The rising cost of IVIG therapy is expected to be a significant impediment to market growth. Immunoglobulin infusions are typically given every 3 to 4 weeks, and the treatment is repeated 12-16 times per year. Depending on the severity of the patient's condition, the anticipated expense of IVIG is USD 73.89 per gram, with a total cost of USD 10,000.
List of Prominent Players in the Intravenous Immunoglobulin Market:
• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc
Market Dynamics:
Drivers-
The rise in the geriatric population, the increased acceptance of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders are all key drivers driving the market growth. With new product launches and approvals, the immunoglobulin market is expected to develop in the future. IVIG therapies are in high demand for treating acquired and primary immunodeficiency illnesses since they are the most effective and only viable therapy option. Furthermore, inactive lifestyle practices, such as eating saturated fats, salt, and sweets, as well as a deficiency of physical exercise and excessive alcohol use, have contributed to an increase in the prevalence of these diseases.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/1874
Challenges:
The high cost of intravenous immunoglobulin therapy will limit their usage, limiting market revenue growth to some extent over the projection period. The supply chain may be a source of concern due to a scarcity of raw materials, and various countries' severe regulatory policies would stifle business expansion. Immunoglobulin therapy, as one of the most technologically advanced therapies, is quite expensive. One of the major problems impeding the growth of the IVIG market is the high cost of medicines. Furthermore, plasma collection, purification, and scarcity are all quite expensive due to modern technologies and the creation of appropriate healthcare infrastructure. As a result, the issue of the plasma supply chain is prevalent in most parts of the world.
Regional Trends:
The North America Intravenous Immunoglobulin market is expected to register a major market share in revenue and is projected to grow at a high CAGR shortly. The country's sophisticated and well-structured healthcare system, a growing emphasis on research and development, and the strong presence of industry players drive market expansion. Besides, Asia Pacific had a considerable share in the market, Increasing awareness and forthcoming opportunities for the use of immunoglobulin-based medicines to treat primary immunological deficiencies in conjunction with an ageing population.
Recent Developments:
• In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
• In January 2022, Argenx SE, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) had approved VYVGART (efgartigimod alfa) intravenous infusion for the therapy of adult patients with generalized myasthenia gravis (gMG) who have not answered adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1874
Segmentation of Intravenous Immunoglobulin Market-
By Application-
• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others
By Distribution Channel-
• Hospital Pharmacy
• Specialty Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Get more information: @
https://www.insightaceanalytic.com/report/intravenous-immunoglobulin-market-/1874
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1874
Immunoglobulins are made from a large human plasma pool obtained from at least 100 donors. The intramuscular route of administration is a traditional procedure that is no longer favoured due to its unpleasantness. In recent years, intravenous immunoglobulin has been a lifeline for people with impaired immune systems. The increasing incidences of target disorders, such as primary immunodeficiency disorders, are expected to expand the market. The rising frequency of immunodeficiency illnesses, technological breakthroughs and investments, rising acceptance of immunoglobulin therapy, and an ageing population will likely fuel market revenue growth over the forecast period. IVIG is a sterile, concentrated set of antibodies from healthy persons injected directly into a vein. It is used to treat immune system disorders or to increase immunological response. The expense of diagnosing and treating demyelinating illness is exceptionally high. The rising cost of IVIG therapy is expected to be a significant impediment to market growth. Immunoglobulin infusions are typically given every 3 to 4 weeks, and the treatment is repeated 12-16 times per year. Depending on the severity of the patient's condition, the anticipated expense of IVIG is USD 73.89 per gram, with a total cost of USD 10,000.
List of Prominent Players in the Intravenous Immunoglobulin Market:
• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc
Market Dynamics:
Drivers-
The rise in the geriatric population, the increased acceptance of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders are all key drivers driving the market growth. With new product launches and approvals, the immunoglobulin market is expected to develop in the future. IVIG therapies are in high demand for treating acquired and primary immunodeficiency illnesses since they are the most effective and only viable therapy option. Furthermore, inactive lifestyle practices, such as eating saturated fats, salt, and sweets, as well as a deficiency of physical exercise and excessive alcohol use, have contributed to an increase in the prevalence of these diseases.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/1874
Challenges:
The high cost of intravenous immunoglobulin therapy will limit their usage, limiting market revenue growth to some extent over the projection period. The supply chain may be a source of concern due to a scarcity of raw materials, and various countries' severe regulatory policies would stifle business expansion. Immunoglobulin therapy, as one of the most technologically advanced therapies, is quite expensive. One of the major problems impeding the growth of the IVIG market is the high cost of medicines. Furthermore, plasma collection, purification, and scarcity are all quite expensive due to modern technologies and the creation of appropriate healthcare infrastructure. As a result, the issue of the plasma supply chain is prevalent in most parts of the world.
Regional Trends:
The North America Intravenous Immunoglobulin market is expected to register a major market share in revenue and is projected to grow at a high CAGR shortly. The country's sophisticated and well-structured healthcare system, a growing emphasis on research and development, and the strong presence of industry players drive market expansion. Besides, Asia Pacific had a considerable share in the market, Increasing awareness and forthcoming opportunities for the use of immunoglobulin-based medicines to treat primary immunological deficiencies in conjunction with an ageing population.
Recent Developments:
• In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
• In January 2022, Argenx SE, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) had approved VYVGART (efgartigimod alfa) intravenous infusion for the therapy of adult patients with generalized myasthenia gravis (gMG) who have not answered adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1874
Segmentation of Intravenous Immunoglobulin Market-
By Application-
• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others
By Distribution Channel-
• Hospital Pharmacy
• Specialty Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Get more information: @
https://www.insightaceanalytic.com/report/intravenous-immunoglobulin-market-/1874
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
